<DOC>
	<DOCNO>NCT01109615</DOCNO>
	<brief_summary>This study aim investigate efficacy safety combination pemetrexed gemcitabine heavily pre-treated , chemotherapy resistant colorectal cancer patient KRAS mutation .</brief_summary>
	<brief_title>Pemetrexed Gemcitabine Treatment Resistant Patients With Metastatic Colorectal Cancer KRAS Mutations</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologically verify adenocarcinoma colon rectum Age &gt; 18 Metastatic colorectal cancer progress chemotherapy regimen contain fluoropyrimidines , oxaliplatin irinotecan . KRAS mutation primary tumour metastasis . Measurable disease accord RECIST ECOG performance status 0 , 1 2 Adequate function liver , kidneys bone marrow measure biochemistry ( max . 2 week enrolment ) EDTA clearance : Uncorrected GFR &gt; 45 ml/min . Neutrophilocytes ≥1.5 x 10^9/l , leukocytes ≥3.0 x 10^9/l , thrombocyte ≥100x10^9/l ALAT ≤ 3 x upper normal value ( ULN ) , bilirubin ≤ 3 x upper normal value , Aptt INR normal ( 23 AC treatment ) . ( ALAT basic phosphatase ≤ 5 x upper normal value case liver metastasis ) . Blood sample paraffin embed tissue primary tumour and/or metastases translational research . Fertile men woman ( woman &lt; 2 year last menstruation ) must use efficient birth control . Signed informed consent . Clinically significant concurrent disease make patient unfit participation study accord investigator . Other malignant disease within 5 year prior study enrolment , except planocellular basal cell carcinoma skin carcinomainsitu cervix . Other experimental treatment within 30 day prior treatment start . Pregnant breastfeed woman . Clinical radiological sign CNS metastasis . Planned radiation target lesion . Concurrent vaccination yellow fever .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Colorectal cancer</keyword>
	<keyword>Metastatic colorectal cancer</keyword>
	<keyword>Treatment resistant</keyword>
	<keyword>Chemotherapy refractory</keyword>
	<keyword>KRAS mutation</keyword>
</DOC>